[1]陈莹,李继昌,剡建华△,等.生长抑素联合白蛋白注射液治疗急性胰腺炎临床疗效及安全性研究[J].陕西医学杂志,2018,(11):1487-1489,1506.
　Chen Ying,Li Jichang,Yan Jianhua,et al.Clinical efficacy and safety of somatostatin combined with albumininjection in the treatment of acute pancreatitis[J].,2018,(11):1487-1489,1506.
点击复制

生长抑素联合白蛋白注射液治疗急性胰腺炎临床疗效及安全性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年11期
页码:
1487-1489,1506
栏目:
药物与临床
出版日期:
2018-11-29

文章信息/Info

Title:
Clinical efficacy and safety of somatostatin combined with albumininjection in the treatment of acute pancreatitis
文章编号:
0.3969/j.issn.1000-7377.2018.11.036
作者:
陈莹1; 李继昌1; 剡建华2△; 刘海霞1; 吴育美1; 薛挺1
1.陕西省宝鸡市中心医院（宝鸡721008），2.陕西省咸阳市中心医院（咸阳 712000）
Author(s):
Chen Ying; Li Jichang; Yan Jianhua; et al.
Baoji Central Hospital in Shaanxi Province（Baoji 721008）
关键词:
胰腺炎;  急性坏死性/药物疗法生长抑素/治疗应用白蛋白/治疗应用
Keywords:
Pancreatitis;  acute necrotizing/drug therapySomatostatin/therapeutic useAlbumins/ therapeutic use
分类号:
R657.51
文献标志码:
A
摘要:
目的：探讨生长抑素联合白蛋白注射液治疗急性胰腺炎（SAP）的临床效果及安全性。方法：将符合纳入排除标准的120例SAP患者均分为两组，对照组在常规治疗基础上加用生长抑素进行治疗；试验组则加用生长抑素与白蛋白注射液进行联合治疗。记录两组腹胀、腹痛消退时间、血清淀粉酶水平恢复时间及住院时间；测定两组患者治疗前后血清白蛋白、血小板活化因子（PAF）、C反应蛋白（CRP）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）；对比两组并发症及不良反应发生情况。结果：试验组临床总有效率为95.00%，对照组81.67%，两组间差异存在统计学意义（P＜0.05）。与对照组比，试验组腹痛腹胀消失、血清淀粉酶水平恢复及平均住院时间均明显缩短（P＜0.05），血清白蛋白上升及血清炎症因子PAF、CRP、IL-6、TNF-α水平下降程度更明显（P＜0.05），胰腺脓肿及胰腺假性囊肿发生率均明显减少（P＜0.05）；但两组急性肾衰竭、腹腔感染发病率及不良反应发生率间差异无统计学意义（P＞0.05）。结论：与单独使用生长抑素相比，生长抑素与白蛋白注射液联合治疗SAP效果更好，可更好的抑制机体炎症因子释放，改善患者局部血流动力学，预防并发症发生，且安全性良好。
Abstract:
Objective：To investigate the clinical efficacy and safety of somatostatin combined with albumin injection in the treatment of acute pancreatitis (SAP).Methods:120 SAP patients who met the exclusion criteria were divided into two groups. The control group was treated with somatostatin on the basis of routine treatment.The experimental group was treated with somatostatin combined with albumin injection.The time of bloating, abdominal pain subsided, serum amylase recovery and hospital stay was recorded in two groups.The levers of serum albumin, platelet activating factor (PAF), C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured before and after treatment in the two groups.The complications and adverse reactions were compared in the two groups.Results:The total clinical effective rate was 95.00% in the experimental group and 81.67% in the control group,and there was a statistically significant difference between the two groups (P＜0.05).Compared with the control group, the time of abdominal pain disappearance, recovery of serum amylase and average length of stay was significantly shorter in the experimental group (P＜0.05);Serum albumin increased more significantly (P＜0.05), serum inflammatory factors of PAF, CRP, IL-6, TNF-α levels decreased more significantly(P＜0.05);The incidence of pancreatic abscesses and pancreatic pseudocysts was significantly reduced (P＜0.05).However, there was no significant difference in the incidence of acute renal failure, abdominal infection, and incidence of adverse reactions between the two groups (P＞0.05).Conclusion:Compared with somatostatin alone, somatostatin combined with albumin injection has better effect on SAP, which can better inhibit the release of body inflammatory factors, improve local hemodynamics, prevent complications, and safety good.

参考文献/References:

[1]Zhu Y, Pan X, Zeng H,et al. A study on the etiology, severity, and mortality of 3260 patients with acute pancreatitis according to the revised atlanta classification in jiangxi, china over an 8-year period[J]. Pancreas, 2017, 46(4)：504-509.
[2]Modha K,Chua T,Jang D, et al. Mo1429 validation of the bisap score as a predictor of severe acute pancreatitis, in-hospital mortality and 30 day mortality in an academic hospital system[J]. Gastroenterology, 2016, 150(4)：710-710.
[3]王新平,方卫华,高庆林.重症急性胰腺炎患者预后与血浆白蛋白变化相关性分析[J].局解手术学杂志, 2015,24(5)：559-561.
[4]李文冬,王静,辛小龙.中西医结合治疗原发性肾病综合征疗效观察[J].陕西中医,2017,38(10)：1411-1412.
[5]汪明灯,黄顺伟,姜东辉,等.早期目标指导联合血浆液体复苏对重症急性胰腺炎预后影响[J].中华胰腺病杂志,2014,14(2)：115-117.
[6]王雨田,陈岳祥.《中国急性胰腺炎诊治指南(草案)》解读[J].中国实用内科杂志,2009,29(4)：317-319.
[7]闫肃.复方丹参注射液联合生长抑素对急性重症水肿型胰腺炎患者血清PAF水平和T、B淋巴细胞水平的影响[J].现代中西医结合杂志,2016,25(8)：874-876.
[8]范秀平,张春燕,赵清华,等.生长激素联合生长抑素治疗急性胰腺炎及对患者血清炎性因子影响研究[J]. 陕西医学杂志,2015,44(7)：897-899.
[9]吴敏助.复方丹参注射液联合生长抑素治疗重症急性胰腺炎的疗效观察[J].现代消化及介入诊疗,2017, 22(1)：72-74.
[10]虞文魁,石佳靓,朱维铭.外科病人液体复苏应用白蛋白争议与共识[J].中国实用外科杂志,2015,35(2)：142-145.
[11]左橙子,原海燕,徐萍,等.某三甲医院老年患者人血白蛋白使用评价及分析[J].中国药物应用与监测,2015,12(1)：36-39.
[12]王苏,刘茂霞,郑紫丹,等.奥曲肽联合白蛋白治疗重症急性胰腺炎疗效分析[J].现代消化及介入诊疗, 2017，22(5)：635-638.
[13]谢文瑞,阳小雅,吴礼浩,等.生大黄联合白蛋白治疗重症急性胰腺炎[J].中华全科医学,2014,12(2)：174-177.
[14]王刚,韩俊岭,王放,等.国产生长抑素联合丙氨酰谷氨酰胺对急性胰腺炎患者肠道功能的影响[J].中国中西医结合消化杂志,2017,32(7)：511-514.
[15]赵向宁,刘兴贵.前列地尔联合生长抑素治疗重症急性胰腺炎的临床观察[J].实用药物与临床,2013, 16(1)：20-21.
[16]陈章强,洪浪,王洪,等.通心络对AMI延迟介入治疗术后血小板活化因子、血管内皮功能、TIMI血流分级的影响[J].中国中西医结合杂志,2016,36(4)：415-420.

相似文献/References:

[1]刘海平.BISAP、CTSI评分系统对急性胰腺炎病变程度的早期诊断价值[J].陕西医学杂志,2016,(09):1171.
[2]姜保周,艾文婷,刘丹平,等.奥曲肽治疗急性胰腺炎55例疗效评价[J].陕西医学杂志,2016,(09):1231.

更新日期/Last Update: 2018-11-30